CN106458992B - 吡啶基哌啶 - Google Patents

吡啶基哌啶 Download PDF

Info

Publication number
CN106458992B
CN106458992B CN201580027519.1A CN201580027519A CN106458992B CN 106458992 B CN106458992 B CN 106458992B CN 201580027519 A CN201580027519 A CN 201580027519A CN 106458992 B CN106458992 B CN 106458992B
Authority
CN
China
Prior art keywords
spiro
methyl
dihydro
pyridin
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580027519.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106458992A (zh
Inventor
K.席曼
F.施蒂贝尔
M.卡尔德里尼
J.布拉格
A.马林格
D.瓦尔伯
C.林克
S.R.克伦普勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Cancer Research Technology Ltd
Original Assignee
Merck Patent GmbH
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Cancer Research Technology Ltd filed Critical Merck Patent GmbH
Publication of CN106458992A publication Critical patent/CN106458992A/zh
Application granted granted Critical
Publication of CN106458992B publication Critical patent/CN106458992B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580027519.1A 2014-03-27 2015-03-10 吡啶基哌啶 Expired - Fee Related CN106458992B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14001145 2014-03-27
EP14001145.3 2014-03-27
PCT/EP2015/000528 WO2015144290A1 (en) 2014-03-27 2015-03-10 Pyridyl piperidines

Publications (2)

Publication Number Publication Date
CN106458992A CN106458992A (zh) 2017-02-22
CN106458992B true CN106458992B (zh) 2019-03-15

Family

ID=50389770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027519.1A Expired - Fee Related CN106458992B (zh) 2014-03-27 2015-03-10 吡啶基哌啶

Country Status (9)

Country Link
US (1) US9926319B2 (cg-RX-API-DMAC7.html)
EP (1) EP3122739B1 (cg-RX-API-DMAC7.html)
JP (1) JP6434989B2 (cg-RX-API-DMAC7.html)
CN (1) CN106458992B (cg-RX-API-DMAC7.html)
AU (1) AU2015236855B2 (cg-RX-API-DMAC7.html)
CA (1) CA2943659C (cg-RX-API-DMAC7.html)
ES (1) ES2720324T3 (cg-RX-API-DMAC7.html)
IL (1) IL247728B (cg-RX-API-DMAC7.html)
WO (1) WO2015144290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6447304B2 (ja) * 2015-03-27 2019-01-09 Jsr株式会社 液晶配向剤、液晶配向膜及びその製造方法、液晶表示素子、位相差フィルム及びその製造方法、重合体並びに化合物
CA3025492A1 (en) 2015-06-01 2016-12-08 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
KR20180073600A (ko) * 2015-11-03 2018-07-02 루 라이센스 에이비 과증식성 장애의 치료를 위한 화합물
WO2018102452A2 (en) 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
BR112019011044A2 (pt) * 2016-11-30 2019-10-08 Bantam Pharmaceutical, Llc compostos pirazol substituídos e métodos de uso no tratamento de doenças hiperproliferativas
ES3004107T3 (en) 2017-01-30 2025-03-11 Univ Kyoto Novel compound, and method for producing regulatory t cells
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
EP4076443B1 (en) * 2019-12-17 2025-09-10 Merck Sharp & Dohme LLC Substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compound as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
MX2024003619A (es) 2021-09-27 2024-04-19 Univ Kyoto Metodo para producir celulas t.
MX2024006360A (es) 2021-11-24 2024-08-19 Regcell Co Ltd Celula t controlable por inducibilidad humana y metodo para prepararla.
JPWO2023095802A1 (cg-RX-API-DMAC7.html) 2021-11-24 2023-06-01
JPWO2023182328A1 (cg-RX-API-DMAC7.html) 2022-03-23 2023-09-28
TW202421780A (zh) 2022-09-26 2024-06-01 國立大學法人京都大學 T細胞的製造方法
CN119948155A (zh) 2022-09-26 2025-05-06 雷格细胞股份有限公司 含有嵌合抗原受体（car）的诱导性调节性t细胞
CN120676951A (zh) 2023-02-08 2025-09-19 雷格细胞股份有限公司 用于治疗或预防天疱疮的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171202A (zh) * 2008-10-06 2011-08-31 癌症研究技术有限公司 用于治疗癌症的作为wnt信号通路抑制剂的基于吡啶和嘧啶的化合物
CN103328463A (zh) * 2010-11-12 2013-09-25 德国癌症研究中心 作为Wnt通路拮抗剂的色烯衍生物及其类似物
WO2013151708A1 (en) * 2012-04-04 2013-10-10 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2013166396A2 (en) * 2012-05-04 2013-11-07 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9834541B2 (en) * 2012-10-08 2017-12-05 Cancer Research Technology Limited 2-aminopyridine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171202A (zh) * 2008-10-06 2011-08-31 癌症研究技术有限公司 用于治疗癌症的作为wnt信号通路抑制剂的基于吡啶和嘧啶的化合物
CN103328463A (zh) * 2010-11-12 2013-09-25 德国癌症研究中心 作为Wnt通路拮抗剂的色烯衍生物及其类似物
WO2013151708A1 (en) * 2012-04-04 2013-10-10 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2013166396A2 (en) * 2012-05-04 2013-11-07 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof

Also Published As

Publication number Publication date
US9926319B2 (en) 2018-03-27
AU2015236855A1 (en) 2016-11-10
AU2015236855B2 (en) 2018-11-01
JP6434989B2 (ja) 2018-12-05
US20170107222A1 (en) 2017-04-20
WO2015144290A1 (en) 2015-10-01
CN106458992A (zh) 2017-02-22
CA2943659C (en) 2023-04-25
EP3122739B1 (en) 2019-01-16
ES2720324T3 (es) 2019-07-19
WO2015144290A8 (en) 2015-12-23
JP2017510590A (ja) 2017-04-13
CA2943659A1 (en) 2015-10-01
IL247728B (en) 2019-12-31
EP3122739A1 (en) 2017-02-01
IL247728A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CN106458992B (zh) 吡啶基哌啶
AU2019259653B2 (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
KR102628675B1 (ko) 벤즈이미다졸론 유래된 bcl6의 저해제
JP6317360B2 (ja) ２−アミノピリジン化合物
IL308983A (en) Pyridazinones as parp7 inhibitors
JP2025183201A (ja) アデノシンａ２ａ受容体のアンタゴニスト
AU2012311184A1 (en) Pyrrolopyrimidine and purine derivatives
CA2931034A1 (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
EP3183239B1 (en) Indazoles
US20230063457A1 (en) Dna-pk inhibiting compounds
AU2019395201A1 (en) Cycloalkane-1,3-diamine derivative
CN117529476A (zh) 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190315